FDA grants de novo for the HemoSonics’ Quantra System
March 13, 2019 : Stago is proud to announce that HemoSonics, a Stago Group company, has been granted de novo marketing authorization by the FDA for its revolutionary diagnostic device Quantra Hemostasis Analyzer platform, and its initial QPlus cartridge. The system is now commercially available in the USA.
Read more
Stago Webinar now available on-demand!
The Stago webinars have successfully gathered colleagues from all around the world. If you have missed the live events or are interested in reviewing it, the 30-minute recorded version is now available online 24/7.
Read more
MedLab Middle East 2019: A vintage edition!
The largest medical convention in the Middle East is held each year in Dubai. And it is one of the largest trade shows in the world.
Read more
Stago environmental policy: unwavering support at all levels of the company
We control our consumption of resources as part of a global approach in line not only with our corporate strategy, but also an environmental policy of benefit to all.
Read more
5th volume in Stago’s “Practical Manual in Haemostasis” collection
The last two volumes were devoted to anticoagulants (parenteral, then oral), it made sense that the Clinical Development Department had to turn its attention to another side with the exploration of bleeding disorders.
Read more